SHA: 688356

Sunshine Guojian Posts 24.77% Revenue Growth in First Three Quarters of 2026 as Anmuquitamab and Anfrequitamab Approvals Reshape Its Autoimmune Franchise
Company

Sunshine Guojian Posts 24.77% Revenue Growth in First Three Quarters of 2026 as Anmuquitamab and Anfrequitamab Approvals Reshape Its Autoimmune Franchise

Sunshine Guojian Pharmaceutical Co., Ltd. (SHA: 688336) released its third‑quarter 2026 report, recording total revenue of RMB 1.392 billion (up 24.77% year‑over‑year) and net profit attributable to shareholders of RMB…

Sichuan Biokin's Izalontamab Brengitecan (BL‑B01D1) Gains NMPA Acceptance for HR+/HER2‑ Breast Cancer NDA – Phase III PFS Win Drives Third Tumor‑Type Expansion Bid

Sichuan Biokin’s Izalontamab Brengitecan (BL‑B01D1) Gains NMPA Acceptance for HR+/HER2‑ Breast Cancer NDA – Phase III PFS Win Drives Third Tumor‑Type Expansion Bid

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Raytone Bio Completes Angel Round to Advance iSus® Platform
Company

Raytone Bio Completes Angel Round to Advance iSus® Platform